Nanoparticulate and Controlled Release Compositions Comprising Cefditoren
First Claim
1. A stable nanoparticulate composition comprising:
- (A) particles comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, said particles having an effective average particle size of less than about 2000 nm in diameter; and
(B) at least one surface stabilizer.
9 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
-
Citations
69 Claims
-
1. A stable nanoparticulate composition comprising:
- (A) particles comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, said particles having an effective average particle size of less than about 2000 nm in diameter; and
(B) at least one surface stabilizer. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
- (A) particles comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, said particles having an effective average particle size of less than about 2000 nm in diameter; and
- 26. A controlled release composition comprising a population of particles containing cefditoren, or a salt, derivative, prodrug, or other form thereof, wherein said particles further comprise a modified release coating or, alternatively or additionally, a modified release matrix material, such that the composition following oral delivery to a subject delivers the cefditoren, or a salt, derivative, prodrug, or other form thereof, in a pulsatile or continuous manner
-
46. A controlled release composition comprising a population of nanoparticulate particles which comprise:
- (A) cefditoren, or a salt, derivative, prodrug, or other form thereof; and
(B) a modified release coating or, alternatively or additionally, a modified release matrix material;
such that the composition, following oral delivery to a subject, delivers the cefditoren, or a salt, derivative, prodrug, or other form thereof, in a pulsatile or continuous manner. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
- (A) cefditoren, or a salt, derivative, prodrug, or other form thereof; and
Specification